The city of Gainesville, Florida, currently has 16 active clinical trials seeking participants for Diabetes research studies.
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
Recruiting
This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated only with diet and exercise or with specific diabetes medications. Only people who have previously not managed to lose weight by changing their diet can participate. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesit... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: University of Florida, Gainesville, Florida
Conditions: Obesity, Diabetes Mellitus, Type 2
A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Recruiting
The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD.
Gender:
All
Ages:
Between 30 years and 80 years
Trial Updated:
06/10/2024
Locations: University of Florida, Gainesville, Florida
Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Diseases
iHERO Study: Insurance, Health and Economic Resources Online for Emerging Adults With Type 1 Diabetes
Recruiting
This research study aims to test a financial and health insurance iHERO Toolkit for young adults with type1 diabetes. The iHERO Toolkit was developed over one year with the type 1 diabetes community, The Diabetes Link organization, and experts. Now, the investigators want to understand the impact of the iHERO Toolkit on diabetes self-management, financial stress, and health insurance literacy outcomes. The investigators are doing this study because it will help to better understand how to suppor... Read More
Gender:
All
Ages:
Between 18 years and 30 years
Trial Updated:
05/24/2024
Locations: University of Florida Diabetes Institute, Gainesville, Florida
Conditions: Type 1 Diabetes
STOP-T1D Low-Dose (ATG)
Recruiting
A multi-center, placebo-controlled, double blind, 2:1 randomized control clinical trial testing low-dose ATG vs. placebo in subjects with a 2 year 50% risk of progression to stage 3 T1D.
Gender:
All
Ages:
Between 6 years and 34 years
Trial Updated:
05/24/2024
Locations: University of Florida, Gainesville, Florida
Conditions: Diabetes Mellitus, Type 1
Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
Recruiting
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.
Gender:
All
Ages:
Between 12 years and 35 years
Trial Updated:
05/23/2024
Locations: University of Florida, Gainesville, Florida
Conditions: Diabetes Mellitus, Type 1
Investigation of Rifampin to Reduce Pedal Amputations for Osteomyelitis in Diabetics
Recruiting
The purpose of this research study is to determine if rifampin, an antibiotic (a medicine that treats infections), is effective in treating osteomyelitis (infection of the bone) of the foot in diabetic patients. Despite use of powerful antibiotics prescribed over a long period of time, many diabetic patients remain at a high risk for needing an amputation of part of the foot or lower leg because the osteomyelitis is not cured. Some small research studies have shown that addition of rifampin to o... Read More
Gender:
All
Ages:
Between 18 years and 89 years
Trial Updated:
05/06/2024
Locations: North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida
Conditions: Osteomyelitis, Diabetes, Amputation
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
Recruiting
To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic steatohepatitis (NASH).
Gender:
All
Ages:
Between 21 years and 75 years
Trial Updated:
03/27/2024
Locations: University of Florida, Gainesville, Florida
Conditions: Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Steatohepatitis
Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes
Recruiting
The study is a two-arm, multicenter, double-blinded clinical trial testing sequential therapy with rituximab-pvvr followed by abatacept versus rituximab-pvvr alone in new onset T1D. The primary objective is to test whether the C-peptide response to a 2-hour mixed meal tolerance test, will be improved in participants with new onset T1D who are treated with Abatacept after Rituximab-pvvr compared to those treated with Rituximab-pvvr and placebo 24 months after enrollment.
Gender:
All
Ages:
Between 8 years and 45 years
Trial Updated:
03/13/2024
Locations: University of Florida, Gainesville, Florida
Conditions: Type 1 Diabetes Mellitus
Immune Function and the Progression to T1D
Recruiting
To elucidate the mechanisms by which type 1 diabetes-associated genes; IFIH1, TYK2, IKZF4, as well as total genetic risk, impart functional immunoregulatory abnormalities that result in expansion of self-reactive adaptive immune cells, defective regulatory/effector mechanisms in T cells, inflammatory antigen presenting cells, and abnormal immune function in T cells and B cells.
Gender:
All
Ages:
Between 0 years and 100 years
Trial Updated:
02/27/2024
Locations: Kieran McGrail, Gainesville, Florida
Conditions: Type 1 Diabetes
Diabetes Disparities: Texting to Extend Treatment (DD-TXT)
Recruiting
One way to help Veterans improve their diabetes control is through the use of technology to help provide information, motivation, and reminders necessary to support diabetes self-management. The study will seek input from diverse groups of Veterans living with diabetes to help develop DD-TXT, a new customizable, interactive texting intervention that allows Veterans to choose what kinds of diabetes self-management support they need, and when. This diabetes support will be provided to Veterans thr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/03/2024
Locations: North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida
Conditions: Diabetes Mellitus, Type 2
TrialNet Pathway to Prevention of T1D
Recruiting
Rationale: The accrual of data from the laboratory and from epidemiologic and prevention trials has improved the understanding of the etiology and pathogenesis of type 1 diabetes mellitus (T1DM). Genetic and immunologic factors play a key role in the development of T1DM, and characterization of the early metabolic abnormalities in T1DM is steadily increasing. However, information regarding the natural history of T1DM remains incomplete. The TrialNet Natural History Study of the Development of T... Read More
Gender:
All
Ages:
Between 30 months and 45 years
Trial Updated:
12/20/2023
Locations: University of Florida, Gainesville, Florida
Conditions: Diabetes Mellitus, Type 1
Lactobacillus Johnsonii Supplementation in Adults With T1D
Recruiting
While genetics demonstrated a major risk factor for the development of type 1 diabetes (T1D), microbiota dysbiosis has been suggested as an elicitor in immunological tolerance and of beta cell autoimmunity. The probiotic Lactobacillus johnsonii N6.2 may prevent or restore the gut flora and show systemic impacts and adaptive immunity in the T1D population thereby preserving beta cell function.
Gender:
All
Ages:
Between 18 years and 45 years
Trial Updated:
08/07/2023
Locations: UF Clinical Research Center, Gainesville, Florida
Conditions: Type 1 Diabetes (T1D)